Cleared Traditional

K990325 - QUIKSTRIP DIPSCAN X MULTIDRUG SCREENING DEVICE

K990325 is an FDA 510(k) clearance for QUIKSTRIP DIPSCAN X MULTIDRUG SCREENING..., manufactured by Syntron Bioresearch, Inc.. The device is a Class 2 Toxicology device with product code DKZ cleared through the Traditional 510(k) pathway after a 142-day FDA review.

K990325 · Syntron Bioresearch, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1999
Decision
142d
Days
Class 2
Risk

K990325 is an FDA 510(k) clearance for the QUIKSTRIP DIPSCAN X MULTIDRUG SCREENING DEVICE. Classified as Enzyme Immunoassay, Amphetamine (product code DKZ), Class II - Special Controls.

Submitted by Syntron Bioresearch, Inc. (Simi Valley, US). The FDA issued a Cleared decision on June 24, 1999 after a review of 142 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3100 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Syntron Bioresearch, Inc. devices

FDA 510(k) Submission Details - K990325

510(k) Number K990325 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 02, 1999
Decision Date June 24, 1999
Days to Decision 142 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
55d slower than avg
Panel avg: 87d · This submission: 142d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DKZ Device Classification - Class 2, Special Controls

Product Code DKZ Enzyme Immunoassay, Amphetamine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DKZ Enzyme Immunoassay, Amphetamine

All 184
Devices cleared under the same product code (DKZ) and FDA review panel - the closest regulatory comparables to K990325.
AT HOME DRUG TEST, MODEL 9063
K994237 · Phamatech · Dec 1999
DBSET MULTIDRUG SCREEN TEST KIT
K990681 · Ameritek, Inc. · Jul 1999
MODIFICATION TO 'RAPID DRUG SCREEN' 9-PANEL
K992033 · American Bio Medica Corp. · Jun 1999
ONTRAK TESTCUP M2K, MODEL CAT. 11 1849 8
K990399 · Roche Diagnostics Corp. · Apr 1999
ONTRAK TESTCUP-ER M2K
K990418 · Roche Diagnostics Corp. · Apr 1999
RAPID DRUG SCREEN 5-PANEL WITH METHAMPHETAMINE TEST
K984525 · American Bio Medica Corp. · Feb 1999